GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned

GlaxoSmithKline's Phase IV obligations for its Commit nicotine polacrilex lozenge include a study of consumers who are contraindicated for use of the OTC smoking cessation drug due to underlying health conditions, FDA's Oct. 31 approval letter states